News
AWH
0.7401
-9.74%
-0.0799
Aspira Women’s Health reports Q3 results
Seeking Alpha · 13h ago
Aspira Women’s Health reports Q3 revenue $2.3M, consensus $2.73M
TipRanks · 14h ago
Aspira Womens Health Q3 Sales $2.200M Miss $2.775M Estimate
Benzinga · 14h ago
ASPIRA WOMEN'S HEALTH INC: FULL YEAR 2024 CASH GUIDANCE RECONFIRMED AS $13.0-$14.5 MLN
Reuters · 15h ago
ASPIRA WOMEN’S HEALTH REPORTS SELECTED THIRD QUARTER 2024 FINANCIAL RESULTS
Reuters · 15h ago
Earnings Scheduled For November 14, 2024
Benzinga · 19h ago
KORU Medical Systems Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 1d ago
Earnings Preview For Aspira Womens Health
Benzinga · 1d ago
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 2d ago
Aspira Women's Health Inc <AWH.OQ> expected to post a loss of 24 cents a share - Earnings Preview
Reuters · 2d ago
Weekly Report: what happened at AWH last week (1104-1108)?
Weekly Report · 3d ago
Aspira Women’s Health expands collaboration with Bioreference
TipRanks · 11/07 13:26
ASPIRA WOMEN’S HEALTH EXPANDS CO-MARKETING AND DISTRIBUTION COLLABORATION WITH BIOREFERENCE® TO INCLUDE OVAWATCH®
Reuters · 11/07 13:00
Weekly Report: what happened at AWH last week (1028-1101)?
Weekly Report · 11/04 12:19
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/01 12:10
Aspira Women’s Health Highlights Future Product Developments
TipRanks · 10/29 21:18
Weekly Report: what happened at AWH last week (1021-1025)?
Weekly Report · 10/28 12:08
Aspira Women’s Health issues letter to shareholders
TipRanks · 10/25 12:21
Aspira Women's Health Selected To Receive $10M Award Over A 2-Year Period From ARPA-H's Sprint For Women's Health To Address Critical Unmet Challenges In Women's Health, Champion Transformative Innovations, And Tackle Health Conditions That Uniquely Or Disproportionately Affect Women
Benzinga · 10/23 15:25
Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Barchart · 10/23 10:23
More
Webull provides a variety of real-time AWH stock news. You can receive the latest news about Aspira Womens Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About AWH
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.